Bloqueo del eje renina angiontensina aldosterona (RAAS) en la enfermedad renal diabética. Más allá del control de la hipertensión arterial
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Rico Fontalvo, Jorge | |
| dc.contributor.author | Montejo Hernández, Juan | |
| dc.contributor.author | Vázquez Jiménez, Lourdes | |
| dc.contributor.author | Rodríguez Yánez, Tomás | |
| dc.contributor.author | Daza Arnedo, Rodrigo | |
| dc.contributor.author | Cardona Blanco, María Ximena | |
| dc.contributor.author | López Lozano, Jhon | |
| dc.contributor.author | Plaza Rivero, Mayerlys | |
| dc.date.accessioned | 2023-04-19T22:51:12Z | |
| dc.date.available | 2023-04-19T22:51:12Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | La enfermedad renal diabética (ERD) es una comorbilidad con alta prevalencia a nivel mundial, siendo una de las complicaciones más frecuentes de la diabetes mellitus (DM). La ERD se relaciona con complicaciones cardiovasculares y progresión de la enfermedad renal crónica (ERC), por ello la identificación de factores modificables, como el control de la presión arterial, es uno de los pilares más importantes en el manejo integral. En esta revisión hacemos un recorrido sobre el papel de la hipertensión y el bloqueo del eje renina angiotensina aldosterona (RAAS) en el curso de la ERD y las estrategias terapéuticas orientadas a la reducción de la presión arterial (PA), el bloqueo RAAS y el impacto en resultados renales y cardiovasculares. El objetivo de este artículo es hacer una revisión de las intervenciones más importantes que actúan bloqueando el eje renina angiotensina aldosterona (RAAS) y determinar si estas medidas en los pacientes con ERD, solo tienen impacto en el control de la presión arterial o si también son estrategias de nefro y cardio-protección. Conclusión: La ERD es una de las complicaciones más frecuentes de la diabetes mellitus (DM). El control de la PA sigue siendo un pilar fundamental para lograr estos objetivos. Los bloqueadores del RAAS (iECAS y BRAs) son los antihipertensivos de elección con efecto terapéutico por el bloqueo RAAS y esto les permite tener además del control de la PA, efectos nefroprotectores y cardioprotectores importantes en pacientes con ERD, sobre todo cuando hay la presencia de albuminuria. Evaluamos que además de los inhibidores de la enzima convertidora de angiotensina (iECAs) y los bloqueadores del receptor de angiotensina (BRAs), vienen tomando importancia los antagonistas selectivos del receptor mineralocorticoide (ARM) como Finerenona. | spa |
| dc.description.abstract | Diabetic kidney disease (DKD) is a comorbidity with a high worldwide prevalence, and one of the most frequent complications of diabetes mellitus (DM). CKD is related to cardiovascular complications and the progression of chronic kidney disease (CKD), therefore the identification of modifiable factors, such as blood pressure control, is one of the most important pillars in comprehensive management. In this review, we will analyze the role of hypertension and the renin-angiotensin-aldosterone system (RAAS) and its suppression in the course of CKD, and therapeutic strategies aimed at reducing blood pressure (BP), RAAS blockade, and the impact on renal and cardiovascular outcomes. The objective of this article is to review the most important interventions that act by blocking the renin-angiotensin-aldosterone system (RAAS) and to determine if these measures in patients with CKD only have an impact on blood pressure control or if they are also nephron and cardio-protective strategies. Conclusion: DKD is one of the most frequent complications of diabetes mellitus (DM). BP control continues to be a fundamental pillar to achieve these objectives. RAAS blockers (iECAS and ARBs) are the first-line antihypertensive with a therapeutic effect due to RAAS blockade and this allows them to have, in addition to BP control, important nephroprotective and cardioprotective effects in patients with CKD, especially when there is albuminuria. We evaluated that in addition to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), selective mineralocorticoid receptor antagonists (MRA) such as Finerenone are gaining importance. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.citation | Rico Fontalvo J, Montejo Hernández J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Cardona Blanco MX, et al. Bloqueo del eje renina angiontensina aldosterona (RAAS) en la enfermedad renal diabética. Más allá del control de la hipertensión arterial. An. Fac. Cienc. Méd. (Asunción), Abril - 2023; 56(1): 46-57 | spa |
| dc.identifier.doi | http://dx.doi.org/10.18004/anales/2023.056.01.46 | |
| dc.identifier.issn | 23132841 | |
| dc.identifier.issn | 18168949 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/12257 | |
| dc.language.iso | spa | spa |
| dc.publisher | EFACIM. Editorial de la Facultad de Ciencias Médicas - Universidad Nacional de Asunción | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Anales de la Facultad de Ciencias Médicas | spa |
| dc.source | An. Fac. Cienc. Méd. (Asunción) | eng |
| dc.source | Vol 56, No 1, (2023) | |
| dc.subject | Enfermedad renal diabética | spa |
| dc.subject | Hipertensión arterial | spa |
| dc.subject | Eje renina angiotensina aldosterona | spa |
| dc.subject | Inhibidores de la enzima convertidora de angiotensina | spa |
| dc.subject | Bloqueadores del receptor de angiotensina | spa |
| dc.subject | Enfermedad cardiovascular | spa |
| dc.subject | Diabetic kidney disease | eng |
| dc.subject | Hypertension | eng |
| dc.subject | Renin-angiotensin-aldosterone system | eng |
| dc.subject | Angiotensin-converting enzyme inhibitors | eng |
| dc.subject | Angiotensin receptor blockers | eng |
| dc.subject | Cardiovascular disease | eng |
| dc.title | Bloqueo del eje renina angiontensina aldosterona (RAAS) en la enfermedad renal diabética. Más allá del control de la hipertensión arterial | spa |
| dc.title.translated | Renin angiotensin aldosterone system (RAAS) and its suppression in diabetic kidney disease. Control of arterial hypertension and beyond | eng |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Fontalvo JER. Guía de práctica clínica para la enfermedad renal diabética. Rev Colomb Nefrol [Internet]. 27 de mayo de 2021 [citado 28 de junio de 2022];8(2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/561 | spa |
| dcterms.references | Rico Fontalvo JE, Rico Fontalvo JE. Enfermedad renal diabética: de cara a la prevención, diagnóstico e intervención temprana. Rev Colomb Nefrol. diciembre de 2020;7(2):15-6. | spa |
| dcterms.references | Daza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, Leal-Martínez V, Abuabara-Franco E, Raad-Sarabia M, Montejo-Hernández J, Cardona-Blanco M, Cabrales-Juan J, Uparella-Gulfo I, Montiel LS. Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Med. 2021 Sep 29;3(6):1065-1073 | eng |
| dcterms.references | Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol. 3 de enero de 2022;23(1):9. | eng |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Cardona-Blanco MX, Leal-Martínez V, Abuabara E, et al. SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J Clini Nephrol. 2020; 4: 044-055. | eng |
| dcterms.references | de Sá JR, Rangel EB, Canani LH, Bauer AC, Escott GM, Zelmanovitz T, et al. The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. Diabetol Metab Syndr. 11 de junio de 2022;14(1):81. | eng |
| dcterms.references | Lopera Vargas JM, Rico Fontalvo JE, Melgarejo R. E, Castillo Barrios GA, Ramirez Rincon A, Gomez Perea AM, et al. Efecto de terapias farmacológicas para el control glicémico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares. Rev Colomb Nefrol. 2020;7(1):44-59. | spa |
| dcterms.references | Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ. 29 de octubre de 1988;297(6656):1086-91. | eng |
| dcterms.references | Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 10 de febrero de 2015;313(6):603-15. | eng |
| dcterms.references | Rico Fontalvo J, Aroca-Martínez G, Daza-Arnedo R, Raad-Sarabia M, Torres JL, Pajaro-Galvis N, et al. Enfermedad renal diabética no proteinúrica: Estado del arte. Rev Nefrol Diálisis Traspl. 31 de diciembre de 2022;42(04):330-9. | spa |
| dcterms.references | Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 14 de julio de 2003;163(13):1555-65. | eng |
| dcterms.references | Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol JASN. julio de 2005;16(7):2170-9. | eng |
| dcterms.references | Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet Lond Engl. 1 de mayo de 2021;397(10285):1625-36. | eng |
| dcterms.references | SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 26 de noviembre de 2015;373(22):2103-16. | eng |
| dcterms.references | Rico Fontalvo JE, Vázquez Jiménez LC, Rodríguez Yánez T, Daza Arnedo R, Raad M, Montejo Hernandez JD, et al. Enfermedad renal diabética: puesta al día. Rev An Fac Cienc Médicas. 2022;55(3):86-98. | spa |
| dcterms.references | Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 20 de septiembre de 2001;345(12):861-9. | eng |
| dcterms.references | Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 20 de septiembre de 2001;345(12):870-8. | eng |
| dcterms.references | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl. 12 de septiembre de 1998;352(9131):854-65. | eng |
| dcterms.references | Villarosa IP, Bakris GL. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. septiembre de 1998;12(9):653-5. | eng |
| dcterms.references | Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet Lond Engl. 7 de agosto de 2010;376(9739):419-30. | eng |
| dcterms.references | Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, et al. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis Off J Natl Kidney Found. abril de 2022;79(4):457-79. | eng |
| dcterms.references | James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 5 de febrero de 2014;311(5):507-20. | eng |
| dcterms.references | de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 1 de diciembre de 2022;45(12):3075-90. | eng |
| dcterms.references | Siebenhofer A, Plank J, Horvath K, Berghold A, Sutton AJ, Sommer R, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med J Br Diabet Assoc. enero de 2004;21(1):18-25. | eng |
| dcterms.references | Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 9 de octubre de 2004;329(7470):828. | eng |
| dcterms.references | Navarro JF, Milena FJ, Mora C, León C, García J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 2006;26(6):562-70. | eng |
| dcterms.references | ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 10 de abril de 2008;358(15):1547-59. | eng |
| dcterms.references | Price DA, Porter LE, Gordon M, Fisher ND, De’Oliveira JM, Laffel LM, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol JASN. noviembre de 1999;10(11):2382-91. | eng |
| dcterms.references | Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet Lond Engl. 28 de mayo de 1983;1(8335):1175-9. | eng |
| dcterms.references | Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 20 de septiembre de 2001;345(12):870-8. | eng |
| dcterms.references | Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol. abril de 2005;42 Suppl 1:S42-49. | eng |
| dcterms.references | Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 6 de agosto de 2002;106(6):672-8. | eng |
| dcterms.references | Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am J Hypertens. febrero de 2008;21(2):172-6. | eng |
| dcterms.references | Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 4 de noviembre de 2004;351(19):1941-51. | eng |
| dcterms.references | Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. febrero de 2006;24(2):403-8. | eng |
| dcterms.references | Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, et al. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. Clin J Am Soc Nephrol CJASN. 7 de diciembre de 2015;10(12):2159-69. | eng |
| dcterms.references | Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 6 de diciembre de 2012;367(23):2204-13. | eng |
| dcterms.references | Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia. junio de 1994;37(6):604-9. | eng |
| dcterms.references | Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. junio de 2004;65(6):1991-2002. | eng |
| dcterms.references | Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic Kidney Disease: Current and Future. Diabetes Metab J. enero de 2021;45(1):11-26. | eng |
| dcterms.references | Arnedo RD, Fontalvo JER, Salcedo NA, Alfaro M, Torrejano DN, Blanco MC, et al. Finerenone y su papel en la enfermedad renal diabética. Estado del arte. Arch Med. 2022;18(1):5. | spa |
| dcterms.references | Hou J, Xiong W, Cao L, Wen X, Li A. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis. Clin Ther. septiembre de 2015;37(9):2086-2103.e10. | eng |
| dcterms.references | Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 15 de abril de 2004;93(8):990-6. | eng |
| dcterms.references | Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. diciembre de 2019;37(12):2307-24. | eng |
| dcterms.references | Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 3 de diciembre de 2020;383(23):2219-29. | eng |
| dcterms.references | Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 9 de diciembre de 2021;385(24):2252-63. | eng |
| dcterms.references | Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 10 de febrero de 2022;43(6):474-84. | eng |
| dcterms.references | Fontalvo JR, Daza Arnedo R, Aguilar Salcedo N, Alfaro M, Navas Torrejano D, Cardona Blanco M, Uparella Gulfo I, Raad Sarabia M, Abuabara Franco E, Cabrales J. New evidence in the treatment of diabetic kidney disease: what is finerenone’s contribution?. Rev. Colomb. Nefrol. [Internet]. 2022 Dec. 14 [cited 2023 Feb. 14];9(3). Available from: https://revistanefrologia.org/index.php/rcn/article/view/603 | eng |
| dcterms.references | Rico-Fontalvo J, et al. Consenso de la Sociedad Latinoamericana de Nefrología e Hipertensión en relación con el papel de los antagonistas del receptor mineralocorticoide en enfermedad renal crónica. Nefrología Latinoamericana 2022:19(2):116-128. DOI: 10.24875/NEFRO.22000034. | spa |
| oaire.version | info:eu-repo/semantics/publishedVersion | spa |